BiotecHEART™-Breakthrough
There is no impossible. And in 2019 the impossible is being topped as the year will prove to be one of the most successful years for biotech & medtech companies, irrespective of the on-going www.biotech-wars.com . In fact, the last 3 months of 2019 will go down as one of the most prolific times for biotech medicines.
This year, 2019, has been a magnificent year for all who need medicine. 2019 has been a breakthrough year for many biotech companies and their pipeline/lifelines are prepared for another successful year in 2020 – www.biotecHeart.com
There is also continued increased interest in biotech buy-outs as more companies seek out partners in product development.
Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
Merck to Acquire ArQule, Advancing Leadership in Oncology
And there have been many clinical tests involving combinations of successful medicines and in many cases the combinations are with another biotech partner’s medicine. One example is = IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) (ABBV) (JNJ) (OTCQX:RHHBY)
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
Patient Resources & Information for IMBRUVICA® (ibrutinib)
Another example is = Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer (OTCQX:RHHBY) (CELG)
FDA Approves Genentech's Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Another example is = Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Mon December 2, 2019 8:00 AM|Business Wire|About: OTCPK:ALPMY, SGEN (MRK)
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Merk & AstraZeneca continue to work together with their successful med = LYNPARZA® (olaparib).
LYNPARZA (olaparib) more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer
LYNPARZA (olaparib) improved the time women lived without disease progression to 22 months in the broad population and to 37 months in hrd-positive patients as 1st-line maintenance treatment with bevacizumab for newly diagnosed advanced ovarian cancer
here is another on 12/7/2019
= Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Sat December 7, 2019 2:00 PM|Business Wire|About: SGEN (BMY)
Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
https://www.adcetris.com/
11/11/2019 Single's Day/Veterans Day
The most fascinating perspective on all this good biotech news is that it goes largely unnoticed, unless you’re a biotech investor like me or work within the biotech sector, much of this good news is rarely broadcast to a larger investing audience or potential user audience. So much business news broadcast time is devoted to Apple, Google, Facebook, Tesla, Netflix, Amazon, and Microsoft, that there is little time left to broadcast much of this great news. I’ve even heard comments by TV business news analyst’s that the healthcare sector will do well because lots of people are getting older? I guess they think the extraordinary clinical testing successes by so many biotech companies are an anomaly, they are not.
Basically, business news channels and business media sometimes bypass major biotech news almost every day as they did on 11/11/2019, Singles Day/Veterans Day depending on where you live. Regardless, Merck offered wonderful news that same day, for a product that will over time save many lives, many lives in Africa for sure, with little to no mention in the broadcast business news media. There was plenty of news and stories that day on Alibaba sales but nothing on Merck’s (MRK) press release that day? Info on many of these successful products are here = www.biotecNOVA.com
Merck's ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Merck wins European approval for first-ever Ebola vaccine
Merck's ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Remarkably, the success of Merck's KEYTRUDA® (pembrolizumab) also goes largely unnoticed, even though Keytruda success stories and new indications come almost every week and Keytruda has become one of the best-selling drugs in the world
Keytruda Approvals: A Timeline | BioSpace
December 2019 to date has had significant positive and encouraging biotech news, a few noteworthy news posts are below;
Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (NYSE:ASH) Annual Meeting
Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting
Genentech: Press Releases | Sunday, Dec 8, 2019
XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (NYSE:AES)
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (NYSE:SCD) at 61st ASH Annual Meeting and Exposition
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Novartis developing 25+ blockbusters - R&D Day
Biogen's aducanumab showed mixed results in Alzheimer's studies
FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria
FDA OKs new MRSA test from Roche
http://www.pharmexec.com/pd-1-race-china-heats
Sesen +9.2% after successful pre-BLA FDA meeting
https://www.nejm.org/doi/full/10.1056/NEJMoa1813049
Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA
Biotech & China in 2019
And I am seeing more than ever before many approvals this year in China for successful medicines, all of these meds will be eagerly sought after = LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer Thu December 5, 2019 6:45 AM|Business Wire|About: MRK
Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy Tue November 26, 2019 6:45 AM|Business Wire|About: MRK
Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA) Mon November 25, 2019 7:00 PM|PR Newswire|About: OTCPK:ALPMY, PFE
This year so much wonderful and supportive medicines are being introduced that 2019 will no doubt match or exceed last year’s successful biotech products development gains.
Mack Brock - God Of Breakthrough (Acoustic Video)
Respectfully submitted to Seeking Alpha on December 9. 2019
As of December 9, 2019, I remain 100% invested in biotech/medtech companies.
thank you for visiting the heart of biotech™
it’s biotech or nothin’!™
seeking biotech alpha 12/8/2019 the heart of biotech™
seeking biotech alpha 12/8/2019 the heart of biotech™
seekingbiotechalpha.com | danwatson888's Portfolio on GuruFocus.com
Disclosure: I am/we are long ABBV, AZN, AMGN, BMY, PFE, MRK, LLY, CELG, SGEN, RHHBY, NVS.
